AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06742138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be administered at a dose of 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
Study NCT04835272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the Decannulation Protocol With Suctioning
Description: In the intervention group, the decision to decannulate was based on suctioning frequency. Patients underwent decannulation when they had had no more than two aspirations every 8 hours during during a 24-hour period. Patients in this group did not undergo capping trials.
Study NCT05332899 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Type A H3N2 Challenge
Description: The intervention product is a live challenge virus that is manufactured in the USA under Good Manufacturing Practice (GMP). The challenge will be administered intranasally using a sprayer device or by natural exposure to infected participants. Participants will be admitted to the hospital and quarantined for 8 to 12 days for monitoring, and will receive care and supportive treatment as necessary. Participants will be followed for a total of 12 weeks.
Study NCT04129723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stopping biological therapy
Description: Stopping biological therapy The primary endpoint is clinical relapse at 12 months
Study NCT06742138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered at a dose of 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
Study NCT06742138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DARZALEX FASPRO®
Description: DARZALEX FASPRO® will be given 1800 mg subcutaneously at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs
Study NCT04728828 — intervention group
Intervention type: BIOLOGICAL
Intervention: Serological COVID-19 vaccine immunogenicity
Description: Serological test
Study NCT06741657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Litifilimab
Description: Administered as specified in the treatment arm.
Study NCT06741657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI
Description: Administered as specified in the treatment arm.
Study NCT06741657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OBI
Description: Administered as specified in the treatment arm.
Study NCT04926493 — intervention group
Intervention type: BIOLOGICAL
Intervention: microbiological characterization
Description: microbiological characterization of endotracheal tube biofilm
Study NCT06355921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: Anesthesia: Local (Novocaine, Lidocaine, Bupivacaine) Access: transcutaneous Navigation under CT control Cannulas are used: 22G 100 and 150 mm, the size of the electrode corresponds to the size of the cannula The starting power is 20W followed by steps of 10W every 2 minutes until the maximum power is reached, the maximum power is 60W.~In order to prevent infectious complications, two-day antibiotic prophylaxis of Cefazolin (1g) is carried out 3 times a day In order to prevent skin burns with superficially located DFS, the skin is cooled during the procedure.
Study NCT05176574 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: A questionnaire will be developed via the Delphi method, will be pilot tested and implemented to assess physicians' perceptions and behaviors on physical activity and exercise in chronic, non-communicable diseases.
Study NCT06201299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Exercise Program
Description: The program content consists of breathing exercises, upper and lower extremity strengthening with theraband and self-walking. Chest, abdominal and lateral basal breathing exercises will be performed 10 times each. Resistance exercises will be performed as strengthening exercises for the major muscle groups of the upper and lower extremities using medium-hard theraband. Patients will be asked to walk 30 minutes a day on flat ground at 60% workload, for periods calculated according to the 6-minute walk test results (land-based walking).
Study NCT06201299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chair-based Exercise Program
Description: The program content consists of breathing exercises and chair-supported exercises. Chest, abdominal and lateral basal breathing exercises will be performed 10 times each. Chair exercises are given in the exercise brochure. Exercises are performed with a chair support or sitting on a chair. In addition, patients will be asked to walk 30 minutes a day on flat ground at 60% workload, for periods calculated according to the 6-minute walk test results (land-based walking).
Study NCT06165653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5-Minute, Audio-Recorded Guided Mediation Practice
Description: Five different meditation practices will be provided, all of which have been validated in prior research.~* The Body Scan practice consists of instruction in how to direct non-judgmental attention to different regions of the body~* The Mindful Breathing practice consists of focused attention on the breath and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and body sensations~* The Mindfulness of Discomfort practice consists of instruction in how to zoom in to deconstruct discomfort and map each feelings' spatial location, use mindful breathing to zoom out and broaden the field of awareness to include neglected sensory elements, and shift attention from unpleasant feelings to neutral/pleasant sensations or experiences~* The Savoring practice consists of instruction in identifying and amplifying pleasant memories~* The Loving-Kindness practice consists of instruction in cultivating feeling of warmth and compassion toward the self and others
Study NCT05403515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot massage
Description: foot massage
Study NCT05403515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot massage +Aromatherapy group
Description: foot massage and lavender oil inhalation
Study NCT04201210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation
Description: Haploidentical 5+/10 HSCT from a relative, α/β T-depleted
Study NCT04201210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Matched sibling donor transplantation
Description: 10/10 HSCT - matched family donor
Study NCT04889911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Enhancement and Cognitive Therapy- Young Adult, Combined with Coordinated Specialty Care
Description: NECT is a psychosocial intervention focused on addressing the effects of self-stigma on individuals diagnosed with severe mental illnesses. For the present study, the intervention has been modified to address the needs of youth who have recently experienced a first episode of psychosis.
Study NCT06741657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFS
Description: Administered as specified in the treatment arm.
Study NCT06741839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy guided pleural biopsy using medical thoracoscopy
Description: After the completion of the routine thoracoscopic examination, the biopsy location was determined based on the results of chest CT/ ultrasound. The benign and malignant states of pleural lesions were explored by nCLE and image records were collected. Then, the biopsy tissues were collected under the guidance of nCLE.
Study NCT06741839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plerual biopsy using medical thoracoscopy
Description: After the completion of the routine thoracoscopic examination, the biopsy location was determined according to the results of chest CT/ ultrasound, and random pathological biopsy was performed, and biopsy tissues were collected by biopsy forceps.
Study NCT06742424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-L1 antibody
Description: 1200mg intravenously every 3 weeks
Study NCT06742424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15mg/kg intravenously every 3 weeks
Study NCT06742424 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC-FOLFOX
Description: Oxaliplatin 130 mg/m² via hepatic arterial infusion over 3 hours Leucovorin 400 mg/m² via hepatic arterial infusion over 2 hours Fluorouracil 400 mg/m² bolus via hepatic arterial infusion at hour 5, followed by 2400 mg/m² continuous hepatic arterial infusion over 46 hours HAIC treatment repeats every 3 weeks for up to 6 cycles
Study NCT04853797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levcromakalim
Description: 20 min infusion of 1 mg Levcromakalim followed by either oral Ivabradine or Placebo.
Study NCT06041334 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Collection of a urine sample
Description: Collection of a urine sample for analysis of urinary biomarkers and urinary metabolomics (Inclusion and 1 year)
Study NCT06041334 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Magnetic Resonance Imaging of the bladder
Description: Magnetic Resonance Imaging of the bladder (10 adults patients only) (Inclusion and 1 year)
Study NCT06366113 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary rehabilitation
Description: Pulmonary rehabilitation includes :~* Exercise re-training with resumption of physical activities~* therapeutic patient education
Study NCT05332756 — intervention group
Intervention type: OTHER
Intervention: Conservative management
Description: Patients and their first-degree relatives will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
Study NCT04853797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levcromakalim
Description: 20 min infusion of 1 mg Levcromakalim followed by either oral Ivabradine or Placebo.
Study NCT05399446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Body Project
Description: The Diabetes Body Project (DBP) is an adapted version of the Body Project Prevention program designed specifically for individuals with Type 1 Diabetes. DBP consists of six weekly, one-hour long sessions. Group participants complete the exercises from the original Body Project and also new diabetes-specific content, drawn from Olmsted et al. (2002) that is delivered in a dissonance-based interactive format with Socratic questions from group leaders encourage participants to generate their own answers.
Study NCT05399446 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Group
Description: We selected a T1D management/Eating disorder psychoeducational comparison condition to control for expectancy effects and demand characteristics. To match the Diabetes Body Project, the educational lectures will be delivered in 6 1-hour blocks. Topics include basic information about the various EDs, complications of ED behaviors, diabetes and body image, effects of dieting on blood glucose, and the risk of complications.
Study NCT04028479 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker Testing (L)
Description: Patients who have received biomarker testing that could affect prognosis or treatment decisions. This generally excludes testing done to assist in the diagnosis of disease or histology where there is no treatment implication from this testing.
Study NCT04028479 — intervention group
Intervention type: DRUG
Intervention: Systemic Treatment (T)
Description: Patients who have received any treatment as part of their care. This refers to systemic treatment, but also allows other non-drug related interventions such as surgery or radiotherapy as part of the longitudinal care of the patient.
Study NCT04028479 — intervention group
Intervention type: OTHER
Intervention: Patient Reported Outcomes (P)
Description: Patients who have provided information about their disease, treatment course, or experience directly to the study using a patient facing tool or device.
Study NCT05649956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg PO daily
Study NCT05175885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ex vivo normothermic perfusion
Description: Ex vivo normothermic perfusion (EVNP) of the renal graft with the Ark Kidney System
Study NCT05175885 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cold preservation
Description: Static cold storage (SCS) or hypothermic machine perfusion (HMP) of the renal graft
Study NCT04889911 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coordinated Specialty Care
Description: Coordinated Specialty Care is an evidence-based, multimodal intervention for persons who have experienced a first episode of psychosis.
Study NCT04853797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: 15 mg oral Ivabradine.
Study NCT04853797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo (calcium supplements).
Study NCT04889911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinated Specialty Care
Description: Coordinated Specialty Care is an evidence-based, multimodal intervention for persons who have experienced a first episode of psychosis.
Study NCT06034652 — intervention group
Intervention type: DEVICE
Intervention: Integra® Gentrix® Surgical Matrix
Description: Integra® Gentrix® Surgical Matrix is intended for implantation to reinforce soft tissue where weakness exists in patients requiring gastroenterological or plastic \& reconstructive surgery.
Study NCT06493071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcutaneous Auricular Vagus Nerve Stimulation
Description: Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the tVNS R device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA). Pulse width will be set at 100μs and frequency will be set at 25Hz. Parameters will be set for the duration of the intervention consisting of 4 hours of daily stimulation for a period of 30 days.
Study NCT06493071 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Auricular Vagus Nerve Stimulation
Description: Stimulation will target the ear lobe using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA). Pulse width will be set at 100μs and frequency will be set at 25Hz. Participants will perform 4 hours of stimulation per day for a period of 30 days. Stimulation will be applied to the ear lobe in order to ensure participant feel the stimulation while avoiding activation of the vagus nerve.
Study NCT06329297 — intervention group
Intervention type: DEVICE
Intervention: CGM monitor
Description: blood glucose sensor used to monitor interstitial glucose
Study NCT06035198 — intervention group
Intervention type: OTHER
Intervention: Stroke
Description: No intervention
Study NCT05145439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VibratoSleeve Therapeutic Ultrasound Device
Description: The VibratoSleeve is compromised of a 16-transducer array that is mounted within a wrap that conforms to the posterior calf.
Study NCT05031832 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HIV test
Description: HIV test would be offered to self-reported HIV-negative / unknown HIV status MSM to confirm their HIV status
Study NCT06350877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: The physical activity intervention will be a 6-week supervised program. Participation will involve engaging in a weekly 1-h session provided in-person at the campus athletics and recreation centre. Each 1-h session will include: (1) 30 min of behaviour change coaching; and (2) 30 min of supervised and structured physical activity training. The intervention materials will include a behaviour change workbook for facilitating the 30 min of behaviour change coaching. Each week participants will complete the behaviour change workbook in session with the program trainer, whereby the overarching goal is to introduce and reinforce engagement in behaviour change techniques and to facilitate the learning objectives and experiences for each weekly session.
Study NCT06420466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted Feeding
Description: Controlling the eating time to 6 hours per day, but not being prescriptive about the quantity and content of dietary intake.
Study NCT06740318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy
Description: The intervention consists of three motivational interviews with the focus to enhance the participants motivation to enter treatment of alcohol use disorder. the interviews are structured and based on the model Motivational enhancement therapy.
Study NCT05707065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core strengthening exercises
Description: The core muscles training includes transverse abdominis, multifidus, paraspinals, quadratus lumborum, and obliques.
Study NCT05707065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: lower limb PNF technique along with conventional treatment i.e., Rhythmic initiation, slow reversal, stabilizing reversal, and combination of isotones.
Study NCT06320951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat 10 MG
Description: The subject will be randomized, in a double-blind manner to vericiguat 10 mg once daily for a period of 12 weeks.
Study NCT06320951 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subject will be randomized, in a double-blind manner to placebo once daily for a period of 12 weeks.
Study NCT06320951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin Sensitivity Test
Description: An assessment of the insulin sensitivity will be done using the Euglycemic Hyperinsulinemic Clamp, at baseline and after 12 weeks of pharmacological interventions.
Study NCT06320951 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Insulin Sensitivity Test
Description: An assessment of the insulin sensitivity will be done using the Euglycemic Hyperinsulinemic Clamp, at baseline and after 12 weeks of pharmacological interventions.
Study NCT06320951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resting Energy and Exercise Energy Expenditure Assessment
Description: Each participant's Energy Expenditure will be determined using a metabolic cart, at baseline and after 12 weeks of pharmacological interventions.
Study NCT06320951 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resting Energy and Exercise Energy Expenditure Assessment
Description: Each participant's Energy Expenditure will be determined using a metabolic cart, at baseline and after 12 weeks of pharmacological interventions.
Study NCT06320951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Adipose Tissue Biopsy
Description: Participants who consent to participate in the exploratory aim will undergo WAT biopsy to assess UCP1 gene expression from the collected biospecimens, at baseline and after 12 weeks of pharmacological interventions.
Study NCT06738043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Description: A bolus dose of dexmedetomidine (0.5 µg/kg ideal body weight) diluted in 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion at 0.5 µg/kg/h until 10 minutes before the end of surgery.
Study NCT06566521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic paravertebral block
Description: After surgery and before extubation, the patient was positioned in an upper lateral position on the affected side. For patients in the TPVB group, an ultrasound high-frequency linear array probe was used to perform a mid-sagittal scan at the T8-9 spinous process interspace on the affected side. The probe was moved to visualize the T8-9 transverse process and pleura. Using the out-of-plane needling technique, the needle was inserted between the costotransverse ligament and the pleura in the paravertebral space adjacent to the thoracic vertebra. After confirmation of no blood or cerebrospinal fluid return, 30 mL of 0.5% ropivacaine hydrochloride was injected. Under ultrasound guidance, the spread of the medication and downdraft of the pleura could be observed.
Study NCT06320951 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: White Adipose Tissue Biopsy
Description: Participants who consent to participate in the exploratory aim will undergo WAT biopsy to assess UCP1 gene expression from the collected biospecimens, at baseline and after 12 weeks of pharmacological interventions.
Study NCT06320951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI-PET Scan for Brown Adipose Tissue Volume Assessment
Description: Participants who consent to participate in the exploratory aim will undergo PET/MR to BAT volume at baseline and after 12 weeks of pharmacological interventions.